Patterns of medical therapy in patients with peripheral artery disease in a tertiary care centre in Canada

Canadian Journal of Cardiology

Volumn 23, Issue 5, 2007, Pages 357-361

  Kundhal, Kiran K ^a   Chin, Siu Lim ^a   Harrison, Lisa ^a   Nowacki, Barbara ^a   Doobay, Budhendra ^a   Titley, Jacques ^a   Cinà, Claudio ^a   Anand, Sonia S ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Medications; Peripheral arterial disease; Practice patterns

Indexed keywords

ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; BYPASS SURGERY; CANADA; CARDIOVASCULAR RISK; CAROTID ENDARTERECTOMY; CEREBROVASCULAR DISEASE; CIGARETTE SMOKING; CLINICAL PRACTICE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG CONTRAINDICATION; DRUG UTILIZATION; FEMALE; GENERAL HOSPITAL; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIMB AMPUTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PERIPHERAL OCCLUSIVE ARTERY DISEASE; TERTIARY HEALTH CARE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASE; RISK FACTOR;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CANADA; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PHYSICIAN'S PRACTICE PATTERNS; PLATELET AGGREGATION INHIBITORS; RISK FACTORS;

EID: 34249711419     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(07)70768-7     Document Type: Article

References (30)

1. Reeder B, Liu L, Horlick L. Sociodemographic variation in the prevalence of cardiovascular disease. Can J Cardiol 1996;12:271-7.
2. McDaniel MD, Cronenwett JL. Basic data related to the natural history of intermittent claudication. Ann Vasc Surg 1989;3:273-7.
3. Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S, Goodman D. The prevalence of peripheral artery disease in a defined population. Circulation 1985;71:510-5.
4. Murabito J, D'Agostino RB, Silbershatz H, Wilson WF. Intermittent claudication. A risk profile from The Framingham Heart Study. Circulation 1997;96:44-9.
5. Zelis R, Mason DT, Braunwald E, Levy RI. Effects of hyperlipoproteinemias and their treatment on the peripheral circulation. J Clin Invest 1970;49:1007-15.
6. Couch NP. On the arterial consequences of smoking. J Vasc Surg 1986;3:807-12.
7. Reunanen A, Takkunen H, Aromaa A. Prevalence of intermittent claudication and its effect on mortality. Acta Med Scand 1982;211:249-56.
8. Doobay AV, Anand SS. Sensitivity and specificity of the ankle-brachial index to predict future cardiovascular outcomes: A systematic review. Arterioscler Thromb Vasc Biol 2005;25:1463-9.
9. Dagenais OR, Maurice S, Robitaille NM, Gingras S, Lupien PJ. Intermittent claudication in Quebec men from 1974-1986: The Quebec Cardiovascular Study. Clin Invest Med 1991;14:93-100.
10. Hackam DG, Goodman SG, Anand SS. Management of risk in peripheral artery disease: Recent therapeutic advances. Am Heart J 2005;150:35-40.
11. Collaborative overview of randomised trials of antiplatelet therapy - 1: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994;308:81-106. (Erratum in 1994;308:1540).
12. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002;360:7-22.
13. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53. (Errata in 2000;342:748, 2000;342:1376).
14. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet 1986;2:57-66.
15. Tsuyuki RT, Teo KK, Ikuta RM, Bay KS, Greenwood PV, Montague TJ. Mortality risk and patterns of practice in 2,070 patients with acute myocardial infarction, 1987-92. Relative importance of age, sex, and medical therapy. Chest 1994;105:1687-92.
16. Anand SS, Kundi A, Eikelboom J, Yusuf S. Low rates of preventive practices in patients with peripheral vascular disease. Can J Cardiol 1999;15:1259-63.
17. World Health Organization. International Classification of Diseases, Ninth Revision. Volumes 1 and 2. Geneva, 1977-78.
18. Canadian Pharmacists Association. Compendium of Pharmaceuticals and Specialties. Ottawa: 2000.
19. Thomson Micromedex Healthcare Series, version 5.1. Greenwood Village: Thomson Micromedex.
20. Pechacek T, Asma S, Eriksen M. Tobacco: Global burden and community solutions. In: Yusuf S, Cairns JA, Camm AJ, Fallen EL, Gersh BJ, eds. Evidence Based Cardiology. London: BMJ Books, 1998:165-78.
21. Katz DA, Muehlenbruch DR, Brown RL, Fiore MC, Baker TB; AHRQ Smoking Cessation Guideline Study Group. Effectiveness of implementing the agency for healthcare research and quality smoking cessation clinical practice guidelines: A randomized, controlled trial. J Natl Cancer Inst 2004;96:594-603.
22. Manfredi C, Crittenden KS, Cho YI, Gao S. Long-term effects (up to 18 months) of a smoking cessation program among women smokers in public health clinics. Prev Med 2004;38:10-19.
23. Zhu SH, Anderson CM, Tedeschi GJ, et al. Evidence of real-world effectiveness of a telephone quitline for smokers. N Engl J Med 2002;347:1087-93.
24. Yusuf S. Two decades of progress in preventing vascular disease. Lancet 2002;360:2-3.
25. Al-Omran M, Lindsay TF. Should all patients with peripheral arterial disease be treated with an angiotensin-converting enzyme inhibitor? Can J Cardiol 2005;21:189-93.
26. Brown LC, Johnson JA, Majumdar SR, Tsuyuki RT, McAlister FA. Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis. CMAJ 2004;171:1189-92.
27. Okaa RK, Umoh E, Szuba A, Giacomini JC, Cooke JP. Suboptimal intensity of risk factor modification in PAD. Vasc Med 2005;10:91-6.
28. Lange S, Diehm C, Darius H, et al. High prevalence of peripheral arterial disease and low treatment rates in elderly primary care patients with diabetes. Exp Clin Endocrinol Diabetes 2004;112:566-73.
29. Anand S, Cina C, Harrsion L, et al. Improving the medical management of peripheral artery disease patients - a high-risk and undertreated group. Can J Cardiol 2001;17(Suppl C):206B. (Abst)
30. Lappe J, Muhlestein J, Lappe D, et al. Improvements in 1-year cardiovascular clinical outcomes associated with a hospital-based discharge program. Ann Intern Med 2004;141:446-53.